» Subscribe Today!
More of what you want to know.
The Daily News
X

Forgot your password?
Skip Navigation LinksHome >
VOL. 128 | NO. 161 | Monday, August 19, 2013

GTx Says Muscle Drug Misses Late-Stage Study Goals

The Associated Press

Print | Front Page | Email this story | Comments ()

Shares of GTx Inc. plunged Monday after the drug developer said its potential treatment for muscle wasting in lung cancer patients fell short of some main goals in late-stage clinical testing.

The Memphis, Tenn., company said enobosarm failed to meet overall criteria for lean body mass and physical function that it had agreed to with the Food and Drug Administration.

The company's shares sank 64 percent, or $2.66, to $1.49 in Monday morning trading. That put the stock down about 65 percent so far this year.

The company is studying enobosarm in patients with advanced forms of non-small cell lung cancer. There are no drugs approved to prevent or treat muscle wasting in cancer patients. GTx said cancer-induced muscle wasting leads to fatigue and weight loss, which can contribute to a shorter overall survival time.

In January, GTx had said that the FDA would review enobosarm under its fast-track program, which is designed to speed up the approval of drugs that treat serious or life-threatening diseases for which there are few other therapies.

GTx said Monday it would talk to both the FDA and European regulators about the next step forward for the drug.

It said enobosarm did have a consistent effect on lean body mass when compared with a placebo. CEO Dr. Mitchell Steiner said in a statement that the company was confident the drug will provide a clinical benefit and possibly increase patient survival.

GTx focuses on developing treatments for cancer, cancer supportive care and other serious medical conditions.

Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Sign-Up For Our Free Email Edition
Get the news first with our daily email


 
Blog News, Training & Events
RECORD TOTALS DAY WEEK YEAR
PROPERTY SALES 106 418 11,538
MORTGAGES 135 521 14,424
FORECLOSURE NOTICES 0 0 2,278
BUILDING PERMITS 220 913 24,947
BANKRUPTCIES 53 297 8,729
BUSINESS LICENSES 26 119 3,890
UTILITY CONNECTIONS 71 524 13,980
MARRIAGE LICENSES 13 83 3,114

Weekly Edition

Issues | About

The Memphis News: Business, politics, and the public interest.